Skip to main content

Table 2 Anti-HCV Treatment characteristics of patients according to treatment arm

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

 

HIV-negative

 

HIV-positive

 
  

No HAART

NRTI-containing

NRTI-free

 

Arm A

Arm B

Arm C1

Arm C2

 

n = 50

n = 49

n = 49

n = 20

Weight adapted RBV * (GT1/4 infections only)

96

81

77

82

Treatment duration 48 weeks

(GT 2/3 infections only) *

0

35

35

67

Enrollment period */**

    

    2002 - 2004

100

80

55

30

    2005 - 2007

-

20

43

70

  1. * Statistically significant difference comparing arm A with arms B and C (HIV-positive vs. HIV-negative)
  2. ** Statistically significant difference comparing arm B versus C1 versus C2
  3. Data shown as percent of patients
  4. NRTI nucleos(t)ide reverse transcriptase inhibitor, GT HCV genotype, RBV ribavirin